|
|
| |||||||||||||||||||||||||||||||||||||||||
Background Investigations of outbreaks of multidrug-resistant tuberculosis have found low rates of treatment response and very high mortality, and they have mainly involved patients with advanced human immunodeficiency virus (HIV) infection. For patients without HIV infection, one study reported an overall rate of response to treatment of 56 percent, and the mortality from tuberculosis was 22 percent. We investigated treatment response and mortality rates in 26 HIV-negative patients in New York with multidrug-resistant tuberculosis.
Methods We obtained detailed data from seven teaching hospitals in New York City on patients with multidrug-resistant tuberculosis — defined as tuberculosis resistant at least to isoniazid and rifampin — who were HIV-negative on serologic testing. Lengths of times from diagnosis to the initiation of appropriate therapy and from the initiation of appropriate therapy to conversion to negative cultures were assessed. Therapeutic responses were evaluated by both microbiologic and clinical criteria.
Results Between March 1991 and September 1994, 26 HIV-negative patients were identified and treated. Of the 25 patients for whom adequate data were available for analysis, 24 (96 percent) had clinical responses; all 17 patients for whom data on microbiologic response were available had such a response. The median times from diagnosis to the initiation of appropriate therapy and from the initiation of therapy to culture conversion were 44 days (range, 0 to 181) and 69 days (range, 2 to 705), respectively. Side effects requiring the discontinuation of medication occurred in 4 of 23 patients (17 percent) who were treated with second-line antituberculosis medications. The median follow-up for the 23 patients who responded and who received appropriate therapy was 91 weeks (range, 41 to 225).
Conclusions In this report from New York City, HIV-negative patients with multidrug-resistant tuberculosis, contrary to previous reports, responded well to appropriate chemotherapy, both clinically and microbiologically.
Previous studies have found that patients with drug-resistant tuberculosis have lower response rates than patients with drug-susceptible isolates.4,5 Recent investigations of outbreaks of multidrug-resistant tuberculosis have found an extraordinarily high case fatality rate, with the median mortality being reached between 4 and 16 weeks.6,7,8,9 In almost all instances, these outbreaks have involved patients severely immunosuppressed by infection with the human immunodeficiency virus (HIV). More recent data suggest that outcomes can be improved if patients promptly start to receive two or more drugs that have in vitro activity against the multidrug-resistant isolates.10,11,12
The expected outcome in patients not infected with HIV who have multidrug-resistant tuberculosis is less well defined. However, a widely cited study of 171 HIV-negative patients treated from 1973 to 1983 at the National Jewish Center for Immunology and Respiratory Medicine found an overall response rate of 56 percent and a mortality rate attributable to tuberculosis of 22 percent.13
In New York City, because of the recent dramatic increase in cases of tuberculosis and multidrug-resistant tuberculosis, we have had the opportunity to evaluate patients with multidrug-resistant tuberculosis who are not HIV-infected. We describe our experience with 25 patients whose clinical characteristics and outcomes differed dramatically from those of previously published studies.
Methods
We identified cases of multidrug-resistant tuberculosis — defined as tuberculosis caused by Mycobacterium tuberculosis resistant at least to isoniazid and rifampin — through a network of hospital-based physicians who treat patients with tuberculosis at seven teaching hospitals in New York City, including five private hospitals (Bronx–Lebanon Hospital Center, Montefiore Medical Center, New York Hospital, St. Clare's Hospital, and Beth Israel Medical Center) and two public ones (Harlem Hospital Center and North Central Bronx Hospital). Only patients who were found to be HIV-negative by routine serologic testing were included in the review. For patients who met these criteria, detailed data-abstraction forms were completed by physicians at the hospitals where the patients initially received the diagnosis of multidrug-resistant tuberculosis. The forms were designed to obtain information on demographic characteristics, risk factors for tuberculosis infection, the extent and verification of tuberculosis, and the response to, and toxicity of, antituberculosis therapy.
The date of diagnosis of multidrug-resistant tuberculosis was defined as the date of collection of the first specimen from which multidrug-resistant tuberculosis was isolated. The time to the initiation of appropriate therapy was defined as the time from diagnosis to the institution of a regimen containing at least two drugs with in vitro activity against the isolate. For one patient, appropriate therapy was begun 63 days before the date of diagnosis. In the analysis, this patient was assigned a value of zero days from diagnosis to appropriate treatment. Another patient was in remission more than three years after his initial diagnosis, without ever having received appropriate treatment. He was removed from this analysis. The time to culture conversion was defined as the time from the start of appropriate therapy to the collection of the first in a series of two or more consecutive negative cultures at least two weeks apart. A therapeutic response was evaluated on the basis of both microbiologic and clinical criteria. A microbiologic response was defined as negative results of at least two consecutive sputum cultures at least two weeks apart. A clinical response was defined as the resolution of signs and symptoms associated with the diagnosis of tuberculosis. Patients were considered to have completed therapy if they had received a total of at least 18 months of appropriate therapy or if they had received at least 12 months of appropriate therapy after the conversion of their sputum cultures to negative; 13 patients satisfied this criterion. Three additional patients categorized as having completed therapy discontinued appropriate treatment against medical advice after they had clinical or bacteriologic responses or both. The duration of follow-up was defined as the interval between the date appropriate therapy was initiated and the date of the last known contact.
Microbiologic Methods
Standard procedures were used according to the practice of each hospital. Five hospitals used their own laboratories to identify M. tuberculosis and to test for susceptibility to first-line antituberculosis medications, one hospital sent specimens to a commercial laboratory, and one hospital sent specimens to the laboratories of the New York City Department of Health. Bactec radiometric mediums (Becton Dickinson, Towson, Md.) were used by five of the laboratories, and solid mediums were used by the other two.14 Tests for susceptibility to pyrazinamide were not routinely performed until April 1992, and results are included here when they were available. Testing for susceptibility to second-line antituberculosis medications and retesting for susceptibility to first-line drugs were performed for 20 patients (80 percent) by a referral laboratory at one of four institutions: the Centers for Disease Control and Prevention, the New York City Department of Health, the National Jewish Center for Immunology and Respiratory Medicine, and the West Haven Veterans Affairs Hospital.14 For specimens tested by referral laboratories, multidrug resistance was defined by the growth on drug-containing mediums (0.2 µg of isoniazid per milliliter and 1.0 µg of rifampin per milliliter) of more than 1 percent of the colonies that grew on a drug-free (control) medium.
Results
Between March 1991 and September 1994, more than 200 patients received diagnoses of multidrug-resistant tuberculosis and were treated at the seven hospitals. The overwhelming majority of these patients were infected with HIV. During this interval, 26 HIV-negative patients with multidrug-resistant tuberculosis were identified and treated; for 25 of these adequate data were available for analysis. Case finding was complete at all seven hospitals. One hospital cared for seven patients, one for six, one for four, one for three, two for two, and one for one.
The demographic characteristics of the 25 patients are shown in Table 1. The median age at the time of diagnosis was 37 years, and 14 patients (56 percent) were male. Fifteen patients (60 percent) were black, four (16 percent) were Hispanic, four (16 percent) were Asian, and two (8 percent) were white. Of the 10 patients born outside the United States or Puerto Rico, 5 were born in Asia, 3 in Latin America, 1 in Africa, and 1 in Europe.
|
All but four patients (84 percent) had disease localized to the lung or pleura; one had both pulmonary and peritoneal disease, and three had extrapulmonary disease alone (in the lymph nodes, the lumbar vertebrae, and the soft tissues of the scrotum). Nineteen of the 25 patients had no underlying disease before the diagnosis of tuberculosis; of the remaining 6, 2 had diabetes mellitus and end-stage renal disease, 2 had diabetes alone, and 1 patient each had severe rheumatoid arthritis and adenocarcinoma of the lung.
Twenty-four patients (96 percent) had clinical responses. One woman with diabetes mellitus and end-stage renal disease died five days after standard doses of isoniazid, rifampin, ethambutol, and pyrazinamide were initiated. Results of susceptibility tests of her isolate became available post mortem and indicated resistance to isoniazid, rifampin, streptomycin, and ethambutol. No autopsy was performed, but the clinical impression was that she died of overwhelming tuberculosis.
The patterns of susceptibility to the five first-line antituberculosis medications and the treatment regimens used for the 23 patients with responses who received appropriate therapy are summarized in Table 2. Twelve of the isolates (52 percent) were resistant to four or five of the first-line antituberculosis agents. Eight patients had isolates that were resistant to isoniazid and rifampin only. Susceptibility testing was not done for pyrazinamide in eight patients.
|
Three patients underwent therapeutic lobectomies at the discretion of the primary treating physicians. Cultures for one patient became negative only after a lobectomy, despite approximately 15 months of appropriate chemotherapy. The other two patients had culture-negative sputum specimens before surgery, but surgery was performed because of localized cavitary disease found on chest radiography.
The median time from the diagnosis of multidrug-resistant tuberculosis to the initiation of appropriate therapy was 44 days (range, 0 to 181) for the 23 patients who ultimately received at least three drugs with in vitro activity against the multidrug-resistant isolate. All 17 patients for whom data on microbiologic response were available had such responses. The median time to a microbiologic response was 69 days (range, 2 to 705), with a mean of 126 days. The mean was influenced by two extreme values of 705 and 496 days. The first value was that of a patient who was noncompliant for more than 2 years but who subsequently responded after 90 days of appropriate therapy that was directly observed. The patient with the second value responded only after a lobectomy, despite appropriate and prolonged chemotherapy. All 17 patients who had microbiologic responses also had clinical responses, with the resolution of signs and symptoms.
Of the eight patients for whom microbiologic response could not be determined, four did not have follow-up specimens obtained because of the site of disease (lymph nodes, vertebrae, soft tissue of the scrotum, or pleura), and one patient died before follow-up specimens could be obtained. Follow-up sputum specimens were not obtained from three patients. Seven of these eight patients had clinical responses.
As of March 31, 1995, 16 patients (64 percent) had completed a course of therapy without evidence of relapse (Table 3). Seven patients (28 percent) were in remission while still receiving therapy, and one remained in remission without having ever received appropriate therapy. The 16 patients who had completed therapy received quinolones for a median of 568 days (range, 150 to 787). In addition, 13 of these 16 patients received parenteral therapy with either an aminoglycoside or capreomycin (median, 252 days; range, 34 to 595); 8 received ethionamide (median, 570 days; range, 119 to 766); and 7 received cycloserine (median, 559 days; range, 119 to 595).
|
Eight patients had a history of tuberculosis; seven of them completed therapy during the study period. These patients had had tuberculosis for a median of 2.5 years (range, <1 to 6) and had received a median of 3.5 antituberculosis drugs before the initiation of appropriate therapy for their multidrug-resistant tuberculosis. The median time to a microbiologic response in the 7 patients for whom data were available was 79 days, as compared with 62 days in the 10 patients with available data and no history of tuberculosis.
Serious side effects requiring the discontinuation of second-line antituberculosis medication occurred in four patients (17 percent) (Table 4). Nineteen patients had no serious adverse reactions. In addition, 13 patients had six or more months of parenteral therapy with an aminoglycoside or capreomycin or both. Ototoxicity in one patient necessitated the discontinuation of kanamycin.
|
Drug-resistant and multidrug-resistant tuberculosis is a growing problem in the United States. The emergence of resistance may be due to either patient noncompliance1,15 or the transmission of already resistant strains.16,17,18 The Centers for Disease Control and Prevention conducted a nationwide susceptibility survey of tuberculosis cases reported in 1991 and found that 14.2 percent were resistant to at least one drug and 3.5 percent were resistant to both isoniazid and rifampin and therefore considered to be multidrug-resistant.3
The optimal therapy for drug-susceptible tuberculosis is well established after numerous trials comprising thousands of patients. The optimal therapy for drug-resistant tuberculosis, particularly multidrug-resistant tuberculosis, is less well studied and standardized. Mitchison and Nunn reviewed the outcomes of patients with drug-resistant tuberculosis in 12 controlled trials conducted in Africa, Hong Kong, and Singapore.4 Of 8212 patients studied, 1041 (12.7 percent) had tuberculosis with initial resistance to at least one drug and 256 (3.1 percent) had tuberculosis resistant to both isoniazid and streptomycin. Only 11 isolates were resistant to rifampin. Chemotherapy failed in 5 of the 11 patients with tuberculosis resistant to rifampin, and 3 of the remaining 6 patients relapsed after therapy was stopped. These responses are in contrast to the high response rates and few relapses that were seen in patients whose disease was initially resistant to drugs other than rifampin. The authors attributed these findings to the excellent sterilizing activity of both rifampin and pyrazinamide and to the ability of rifampin to help prevent the emergence of drug resistance during treatment.
A recently published study described the outcomes of 171 patients with multidrug-resistant tuberculosis treated over an 11-year period from 1973 to 1983.13 These patients had tuberculosis for a median of six years and had received a median of six drugs before being referred to the National Jewish Center for Immunology and Respiratory Medicine in Denver. Patients were shedding tubercle bacilli that were resistant to a median of six drugs. Outcomes in this group were poor: of 134 patients for whom adequate follow-up data were available, 87 (65 percent) initially responded to chemotherapy and 47 (35 percent) had no response, as manifested by persistently positive cultures. The overall response rate, including relapses, was 56 percent, and the mortality attributable to tuberculosis was 22 percent.
In studies of outbreaks in the early 1990s, patients with the acquired immunodeficiency syndrome (AIDS) and multidrug-resistant tuberculosis had a median survival of 4 to 16 weeks.6,7 In one report, those who were HIV-infected but without a diagnosis of AIDS had a median survival of 14 months.9 Recent reports have described improved outcomes when HIV-infected patients received prompt diagnoses and were treated rapidly with appropriate medications.10,11,12 In our series, the median time from the diagnosis of multidrug-resistant tuberculosis to the initiation of appropriate therapy was 44 days. This relatively short period, as compared with those reported previously, is probably due to three factors: the practice of starting treatment with isoniazid, rifampin, pyrazinamide, and ethambutol for all patients with tuberculosis before the results of susceptibility testing were available; the use of Bactec radiometric mediums; and maintenance of a high index of suspicion for drug-resistant tuberculosis.
We have shown that HIV-negative patients with multidrug-resistant tuberculosis can be expected to have a good response to medical therapy. All of our patients who received appropriate therapy have had clinical and microbiologic responses. There were no relapses or treatment failures during a median follow-up period of 91 weeks. It is still possible that some of these patients will relapse. This group, however, in addition to having the benefits of quinolone therapy, probably represents patients of a different type from those described in the Denver study. The Denver patients, as we have mentioned, were heavily pretreated and were referred after treatment by physicians in their own communities had failed. Many of our patients, on the other hand, probably had primary disease; in fact, only eight of the patients (32 percent) had a history of tuberculosis. As recent studies based on restriction-fragment–length polymorphisms have demonstrated, recent transmission accounts for as much as 40 percent of cases of adult tuberculosis in certain urban populations.16,17 It may be that our results reflect the advantage of treating primary resistant disease, rather than disease in persons exposed intermittently to antituberculosis medication for years, resulting in secondary resistance and damaged lungs. Even our patients with previous tuberculosis, all of whom responded, represented a group different from those treated in the Denver series. They had tuberculosis for a shorter period (2.5 years, vs. 6 for the Denver patients) and were not as heavily pretreated (median number of drugs, 3.5, vs. 6 in Denver). Lastly, as we saw in one of our patients, primary tuberculosis, even when due to a multidrug-resistant strain, may resolve with no effective chemotherapy, although the risk of reactivation clearly remains.
Since this retrospective review is based on the experience of seven hospitals, laboratory techniques and treatment regimens varied. Nevertheless, we conclude that contrary to previous reports, patients without HIV infection who contract multidrug-resistant tuberculosis can be expected to respond to appropriate chemotherapy, both clinically and microbiologically. As in other studies, serious drug toxicity is not unusual, and safer agents are needed. Assessment of the long-term efficacy of this approach awaits several more years of patient follow-up.
We are indebted to Drs. Jonathan W.M. Gold and Barkat A. Fazal for their critical comments, and to Olga Zerafa for assistance in the preparation of the manuscript.
Source Information
From the Bronx–Lebanon Hospital Center, Bronx, N.Y. (E.E.T., S.B., G.T.); St. Clare's Hospital and Health Center, New York (K.S.); New York Hospital–Cornell Medical Center, New York (K.S., S.M.); Harlem Hospital Center, New York (F.M., W.E.-S.); Montefiore Medical Center and North Central Bronx Hospital, Bronx, N.Y. (P.A.); St. Vincent's Medical Center, New York (A.G.); and Beth Israel Medical Center, New York (N.S.).
Address reprint requests to Dr. Telzak at the Division of Infectious Diseases, Bronx–Lebanon Hospital Center, Albert Einstein College of Medicine, 1650 Grand Concourse, Bronx, NY 10457.
References
| |||||||||||||||||||||||||||||||||||||||||
Related Letters:
Multidrug-Resistant Tuberculosis
Iseman M. D., Goble M., Corrêa da Silva L. C., Corrêa da Silva L. M., Di Perri G., Vento S., Concia E., Cazzadori A., Telzak E. E., Sepkowitz K., Turett G.
Extract |
Full Text
N Engl J Med 1996;
334:267-269, Jan 25, 1996.
Correspondence
This article has been cited by other articles:
HOME | SUBSCRIBE | SEARCH | CURRENT ISSUE | PAST ISSUES | COLLECTIONS | PRIVACY | TERMS OF USE | HELP | beta.nejm.org Comments and questions? Please contact us. The New England Journal of Medicine is owned, published, and copyrighted © 2009 Massachusetts Medical Society. All rights reserved. |
Previous
